Sanofi-Pasteur's quad flu vaccine now at the FDA
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review Sanofi-Pasteur's quadrivalent flu vaccine Fluzone (influenza virus vaccine) and an action date is due in the second quarter of 2013. The company is trailing MedImmune (AstraZeneca) and GlaxoSmithKline to market in this new four-pronged approach to seasonal flu prevention. Currently trivalent 'flu vaccines are the norm (containing two A and one B strain), but there is a move towards quadrivalent product with two B strains to provide more comprehensive protection.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.